Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Prospective, Phase II Descriptive Pilot Trial of Belimumab Therapy for Refractory and/or Non-criteria Manifestations of Antiphospholipid Syndrome

NCT05020782 is registered in ClinicalTrials.gov with University of Turin, Italy as lead sponsor.

NCT NCT05020782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05020782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Prospective, Phase II Descriptive Pilot Trial of Belimumab Therapy for Refractory and/or Non-criteria Manifestations of Antiphospholipid Syndrome
Lead sponsor
University of Turin, Italy
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 1, 2022
Completion date
January 1, 2025
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome